GlassScriptPhysician profile
Joseph Zevallos
NPI 1548558471
$2,815.91
in general payments reported to CMS, 2019-2025
15 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $976 · 2023: $358 · 2024: $225 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $499.18 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $326.64 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $271.19 | 2022-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $246.31 | 2021-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.37 | 2022 | |
| Abbvie INC. | $224.85 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $203.15 | 2022 | |
| Novo Nordisk INC | $198.50 | 2021-2022 | |
| Amgen INC. | $125.00 | 2025 | Evenity |
| Mylan Specialty L.P. | $125.00 | 2023 | Yupelri |
| Mimedx Group, INC. | $100.49 | 2024 | |
| Kci USA, INC. | $94.73 | 2023 | Activ.A.C. |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Zevallos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.